Lupus Nephritis
235
48
60
80
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
41 trials with published results (17%)
Research Maturity
80 completed trials (34% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
11.1%
26 terminated out of 235 trials
75.5%
-11.0% vs benchmark
26%
61 trials in Phase 3/4
51%
41 of 80 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 80 completed trials
Clinical Trials (235)
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
US Zamto-cel Autoimmune Diseases
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Lupus Landmark Study: A Prospective Registry and Biorepository
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
CHT105 for the Treatment of Refractory Lupus Nephritis